SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Arthur Ashe — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientArthur Ashe
Date of birth1943-07-10
IdentifiersMRN HR-ML013-SYN-TD; SSN (made up) 000-13-6620
Document date1989-02-09
AuthorVivian Tolliver, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week potassium and creatinine check, second hepatitis B vaccine, and same-day infectious diseases consultation. [S]

History of Present Illness

Mr. Ashe returns four weeks after his first visit and is seen by Dr. Rao of infectious diseases on the same day. He takes bictegravir, emtricitabine, and tenofovir alafenamide each morning and trimethoprim-sulfamethoxazole twice a day, and has missed no doses. He started ezetimibe four weeks ago without muscle aches. He has had no headache, seizure, or weakness, and his right hand feels normal. He has had no rash, fever, cough, or breathlessness, and no chest pain. He is sleeping better than at the first visit and has started to coach again two afternoons a week. He has told no one new about his diagnosis and asked again that his results go only to him. [S]

ElementDetail
AdherenceNo missed doses of any medicine
New medicineEzetimibe for four weeks; no side effects
NeurologicalNo headache, seizure, or weakness
HeartNo chest pain; no nitroglycerin use
PrivacyResults to him only, by secure message

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or night sweats; weight up 0.6 kg
IntegumentaryNegativeNo rash on trimethoprim-sulfamethoxazole
CardiovascularNegativeNo chest pain or palpitations
NeurologicalNegativeNo headache, seizure, numbness, or weakness
PsychiatricNegativeMood improving; sleeping better; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesiumOne tablet by mouth once dailyOral route1988-09-25activeS
Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intakeThree tablets by mouth daily after a 200 mg loading doseOral route1988-09-11 to 1988-10-23completedS
Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intakeThree tablets by mouth every 6 hoursOral route1988-09-11 to 1988-10-23completedS
Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intakeTwo tablets by mouth dailyOral route1988-09-11 to 1988-10-23completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route1988-10-23 to 1989-10-19completedS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1979-07-31activeS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1979-08-01activeS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1989-01-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route1979-08-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1989-02-09Body height185cmS
1989-02-09Body weight72.6kgS
1989-02-09Body mass index (BMI) [Ratio]21.2kg/m2S
1989-02-09Systolic blood pressure116mm[Hg]S
1989-02-09Diastolic blood pressure72mm[Hg]S
1989-02-09Heart rate70/minS
1989-02-09Respiratory rate14/minS
1989-02-09Body temperature36.6CelS
1989-02-09Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1989-02-09Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1989-02-09Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
1989-02-09Creatinine [Mass/volume] in Serum or Plasma1.16mg/dL0.74-1.35 mg/dLNormalS
1989-02-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M79mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1989-02-09Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS

Physical Exam

Vital signs recorded on 1989-02-09; see the Vital Signs section. [S]

SystemFinding
GeneralWell and composed; weight 72.6 kg, blood pressure 116/72
Skin and mouthNo rash; no thrush
CardiovascularRegular rhythm; no murmur; no edema
NeurologicalGrip strength and fine finger movements equal on both sides; no focal deficit

Problems

ProblemClinical statusVerificationCodeProvenance
HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infectionactiveconfirmed B20S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled.
Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapyactiveconfirmed B58.2S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass.
Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1942 and 1946 operationsactiveconfirmed I25.10S — Synthetic modern diagnosis; the history remains D.
Old myocardial infarction at age 36activeconfirmed I25.2S — Synthetic coded history of the documented 1979 heart attack.
Hyperlipidemia, on high-intensity statinactiveconfirmed E78.5S — Synthetic diagnosis; no cholesterol value from his lifetime is used.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHIV-1 viral load4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 monthsUp to date42 copies/mL four weeks ago, falling from 186,000 at diagnosis; next at three months
LaboratoryCD4 countEvery 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ARTUp to date156 cells/uL four weeks ago; next at three months
LaboratoryHIV genotype resistance testAt diagnosis, before ART; again if the viral load reboundsUp to dateNo resistance mutations on the genotype sent before ART in the hospital
LaboratoryHLA-B*5701 testOnly before abacavir is consideredNot indicatedAbacavir is avoided because of its association with myocardial infarction in people with coronary disease
Medication safetyART adherence and drug-interaction review (antacids, calcium, iron, new medicines)Every visitCompleted todayNo missed doses; no antacid, calcium, iron, or new medicine
LaboratoryComplete blood countEvery 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ARTUp to dateHemoglobin 13.0 g/dL, white cells 4.2, platelets 198 four weeks ago; next at three months
LaboratoryPotassium, creatinine, and eGFR1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 monthsCompleted todayPotassium 4.8 mmol/L, creatinine 1.16 mg/dL, eGFR 79; stable
LaboratoryUrine albumin-to-creatinine ratio on tenofovirAt the start of tenofovir and yearlyDeferredNot done when tenofovir alafenamide was started in the hospital or at intake, a deviation from the DHHS and HIVMA guidance. Creatinine is stable, so no harm is evident. Corrective action: urine albumin-to-creatinine ratio ordered with the three-month blood tests
LaboratoryALTEvery 6 months on ART; with symptoms on a statinUp to dateALT 30 U/L four weeks ago
Medication safetyToxoplasma maintenance therapy and stopping criteriaContinue until CD4 above 200 for more than 6 months on ART with a suppressed viral loadCompleted todayTrimethoprim-sulfamethoxazole double strength twice daily, the alternative maintenance regimen; CD4 156, so it continues
Medication safetyPneumocystis prophylaxisWhile CD4 below 200; stop after more than 3 months above 200Completed todayCovered by the trimethoprim-sulfamethoxazole maintenance dose
Medication safetyMycobacterium avium complex prophylaxisNot recommended for people who start ART promptlyNot indicatedOn fully active ART since the hospital
ExaminationNeurological check: headache, seizure, weakness, and right-hand strengthEvery visitCompleted todayNo symptoms; grip and fine finger movements equal
Self-managementHepatitis B vaccine series and antibody checkTwo doses four weeks apart; surface antibody 1 to 2 months after the last doseCompleted todayDose 2 given today; antibody check at three months
Self-managementMeningococcal ACWY vaccineTwo doses at least 8 weeks apart, then every 5 yearsUp to dateDose 1 four weeks ago; dose 2 at three months
Self-managementLive vaccines (MMR, varicella)Contraindicated while CD4 below 200Not indicatedCD4 156; immune to measles, mumps, rubella, and varicella by serology in the hospital
Self-managementPsychosocial support, disclosure on his terms, and U=U counselingEvery visitCompleted todayResults go to him alone by secure message; he has not chosen to tell anyone new; peer support group details given again
SurveyDepression screen (PHQ-9 or PHQ-2)At intake, at six months, and yearlyUp to datePHQ-9 5 four weeks ago; mood improving
ExaminationBlood pressure (goal below 130/80)Every visitCompleted today116/72 mmHg
ExaminationWeight, BMI, and physical activityEvery visitCompleted today72.6 kg, BMI 21.2; coaching two afternoons a week
Self-managementTobacco useEvery visitCompleted todayNever used tobacco
Medication safetyCoronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibeEvery visitCompleted todayTaking all three; atorvastatin 80 mg has no interaction with bictegravir
Medication safetyBeta-blockerFirst year after myocardial infarction, or with LVEF 50 percent or less, angina, or another indicationNot indicatedMyocardial infarction ten years ago; no angina, heart failure, or arrhythmia; blood pressure normal
Self-managementAngina review and chest-pain planEvery visitCompleted todayNo angina; nitroglycerin not used; chest-pain plan reviewed
LaboratoryLipid panel4 to 12 weeks after a change, then every 3 to 12 months; yearly when stableDueLDL 88 mg/dL at intake; ezetimibe added; recheck with the three-month blood tests
LaboratoryLipoprotein(a), once in adulthoodOnce in adulthoodDueNot on record; with the three-month blood tests
ImagingStress testing, coronary imaging, or echocardiographyOnly with new or worsening symptoms; routine surveillance not recommendedNot indicatedNo symptoms
ReferralInfectious diseases consultationAt diagnosis, then as advisedCompleted todaySeen by Dr. Rao today

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]

Guideline basis: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026)

Follow-up: Three-month visit with blood and urine tests, the second meningococcal dose, and the first zoster dose. Results by secure message. Next scheduled visit 1989-04-13: three-month HIV and lipid review. [S]